Where do we go from here? Philip Hopewell, MD

Slides:



Advertisements
Similar presentations
International Security Security UNAIDS INITIATIVE ON HIV/AIDS AND SECURITY NationalSecurityNationalSecurityHumanitarianResponseHumanitarianResponse In.
Advertisements

System Assessment and Benchmarking for Education Results (SABER) Policy Domains Learning for all Low-income Countries Middle-income Countries OECD Countries.
TB epidemiological reviews: baseline to setting country-level targets 9 th Technical Advisory Group and National TB Programme Managers' Meeting Manila,
1 Dr Carmelia Basri Dr Nadia Tarmizi National TB Control Program Indonesia M&E WORKSHOP MEASURE Evaluation, New Delhi, 1Feb2006.
Moving to the final chapter of the AIDS epidemic.
WATER and SANITATION.
World Health Organization
22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60 BRUSSELS Charles S Mgone EDCTP Executive Director.
THE FIGHT TO STOP TB WHAT ARE WE FIGHTING? TUBERCULOSIS: THE WORLD’S NO. 1 KILLER AMONG CURABLE, INFECTIOUS DISEASES But there is hope PEOPLE WHO HAVE.
WHEN May |1 | World Health Editors Network Millennium Development Goals Carla AbouZahr Department of Health Statistics and Informatics.
Family Health International Kenneth F. Schulz, PhD, MBA Science for Global Action and Impact.
2nd Meeting of the Subgroup on Advocacy, Communications and Social Mobilization at Country Level Advocacy, Communication and Social Mobilization Sub Group.
Setting a Target for Maternal Mortality Marjorie Koblinsky, USAID Thomas Pullum, MEASURE DHS Tessa Wardlaw, Danzhen You, UNICEF Lale Say, Doris Chou (WHO)
Small Business Meeting 03 May 2013 Jeffrey Napier, Acting Director of the Office of Acquisition Services Procurement and Grants Office.
Famine the global issue.
Tuberculosis The evolution of a bacterium. 2 World Health Organization (WH.O. declared TB a global health emergency in cases per 100,
Universal access to TB care what is the challenge, what policy, what is being implemented Cancun 3 December 2009 Léopold BLANC and TBS team TBS/STB/WHO.
Implementing the revised TB/HIV indicators and data harmonisation at country level Christian Gunneberg MO WHO Planning workshop to accelerate the implementation.
PEPFAR Investment Strategy (8 years of PEPFAR) Data source : OGAC Budget Total PEPFAR Investment: $21,285,918,291 Saving Lives : Changing the.
AFRICA HIV/AIDS AIDS DATA SOURCE: UNAIDS 2007 REPORT WORLD HEALTH ORGANIZATION.
1 Updating and Validating the Inventory of the Legacy POPs Inventory Workshop 4-5 March 2013, Antalya, Turkey.
Strategies to promote uptake of appropriately formulated paediatric TB drugs Dr Malgosia Grzemska Global TB Programme World Health Organization, Geneva,
The role of prevalence surveys in measuring the burden of TB, progress in TB control and improving early case detection Ikushi Onozaki WHO/STB/TBS Global.
Dr Ral Antic Chair Scientific Committee IUATLD-APR Australia Pre-Conference Workshop 1 National TB Control Program Summary & Remarks.
HIV and related infections in prisoners. HIV and tuberculosis in prisons in sub-Saharan Africa L Telisinghe, S Charalambous, SM Topp, ME Herce, CJ Hoffmann,
Resource Availability for HIV, Overview of the financing situation
Somya Gupta, Reuben Granich
Access to Insurance Initiative
TB-HIV Last updated: January 2017.
Community Representative Update
Overview of Phase II, proposed directions for Phase III
Investment Priorities by Region
Income level n Aware (%) Treated (%) Controlled (%) High
© The Author(s) Published by Science and Education Publishing.
Philippe Glaziou Geneva, 12 October 2009
Tuberculosis (TB): The 22 High-Burden Countries (HBCs)
HIV/AIDS in sub-Saharan Africa July 2002
Novel approaches to TB infection control in private general hospitals in Georgia T Gabunia1, I Khonelidze, N Solomonia, T Merabishvili, M Makharadze,
وضعیت بیماری سل در جهان، منطقه و ایران
Engaging with the Private Sector: A Framework for Public Purchasers
TB-HIV Last updated: March 2018.
By: Dr Mirzaei.
Find and Treat All Missing Persons with TB
Vibrant businesses, better lives.
Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.
World Health Organization
Andy Ramsay Overview of TDR February 2014 Andy Ramsay
ДЭМБ, Сүрьеэтэй тэмцэх стратеги он: Бүсийн хэтийн төлөвлөгөө
Treatment Last updated: November 2018.
TB-HIV Last updated: November 2018.
وضعیت بیماری سل در جهان، منطقه و ایران
Key issues in DOTS implementation
Afghanistan Afghanistan.
Update on HIV and TB situation in SEAR Dr Mukta Sharma RA HIV TB HEP WHO SEARO Global Fund , South-East Asia Constituency Meeting, April 2018,
Global DOTS Expansion: how are we doing?
Essential Drugs and Medicines Policy (EDM) World Health Organization
World Populations and Populations Pyramids Lab
Pediatric HIV Case Finding Strategies
National Prevalence Survey, Cambodia
Overview of TB Epidemiology in the African Region
survey prevalence (%) (year)
Disclaimer This document contains data provided to WHO by member states. Note that some member states only provide aggregate data to WHO, and for these,
REPORTING ON SUPPORT TO STATISTICS
THE GLOBAL EPIDEMIOLOGY OF TUBERCULOSIS WORLD HEALTH ORGANIZATION
Countries of Africa.
Data Availability Last updated: April 2019.
Decade of field experience with TB GeneXpert IAS 2019 Satellite session Mexico, 22 July 2019 By Jean de Dieu IRAGENA Technical Officer Laboratory WHO/AFRO,
Global DOTS Expansion: will we reach the Targets?
Webinar Priority IPC Indicators
WHAT IS TUBERCULOSIS (TB)?
Presentation transcript:

Where do we go from here? Philip Hopewell, MD Curry International Tuberculosis Center University of California San Francisco Good morning (ur afternoor or evening depending on where you are watching this World TB Day program. World TB Day presents us with a good marker, a tie to take stock of where we are in global TB care and control and where we want to go from here.

‘We’re Losing the Fight’: Tuberculosis Batters a Venezuela in Crisis New York Times, March 20, 2018 ‘We’re Losing the Fight’: Tuberculosis Batters a Venezuela in Crisis This is not where we want to go. As described in this article in the New York Times a few days ago, tuberculosis is poised to resurge as it has in Venezuela if/when we let up on the pressure we apply in addressing the disease. Until relatively recently, Venezuela had a very good tuberculosis control program but the current economic crisis has led to striking resurgence in the disease in a country with little ability to fight back.

Recent findings and events Data from recent TB prevalence surveys Examinations of the cascade of TB care Detailed national and sub-national descriptions of pathways to care Shorter, effective regimens for LTBI Ministerial meeting on TB UN General Assembly meeting on TB Part of the reason to take stock and deciode where we go from here is the relatively recent availability of important data

Recent national TB prevalence surveys in Asia and Africa WHO Global Tuberculosis Programme Katherine Floyd, Philippe Glaziou, Irwin Law, Ikushi Onozaki, Babis Sismanidis

Surveys 1990–2017 27 surveys between 2009 and 2015/16 1991 1992 1993 1994 1995 1996 1997 1998 1999 China Thailand Myanmar R. Korea Philippines 2000 2001 2002 2003 2004 2005 2006 2007 2008 China Cambodia Eritrea Indonesia Philippines BNG Viet Nam 2009 2010 2011 2012 2013 2014 2015 2016 2017 Myanmar China Cambodia Gambia Ghana Indonesia Mongolia DPR Korea Ethiopia Nigeria Malawi Zambia Uganda Mozambique Namimbia Lao PDR Rwanda Sudan Zimbabwe Bangladesh Nepal Pakistan Tanzania Kenya South Africa Thailand Philippines Viet Nam All the national TB prevalence surveys since 2009 with the task force guidance adopted symptom and direct chest x-ray screening and smear and culture based diagnosis. Recent surveys introduced NAA (Xpert or LPA) and HIV tests. Other countries indicating interest: Africa- Botswana, Lesotho, Swaziland, Senegal, Ivory Coast, Angola, and repeat survey in Ethiopia. Asia- Afghanistan, East Timor and very importantly India South America- Bolivia and Peru. Completed (16*) *since Task Force subgroup active Field operations completed, analysis ongoing (1) Field operations ongoing (3) Planned (8) 27 surveys between 2009 and 2015/16 20/22 global focus countries (not Mali or Sierra Leone) + 7 more: Lao PDR, Gambia, Sudan, Zimbabwe, Mongolia, DPR Korea, Nepal

Consistent methods since 2009 HIV test offered in most African surveys *Since 2013: + rapid molecular test for at least: 1. All smear-positive specimens; 2. Smear-negative specimens if culture failed

Lessons from prevalence surveys TB is more prevalent than we have thought. Cough is an insensitive indicator of TB. Microscopy is only 40-50% sensitive (compared with culture). False-positive smears are common. Many cases are treated in the private sector. Many “smear positive cases” cannot be confirmed by culture. (Is problem with smear or with culture?)

4 million “missing” cases Case notification gap 4 million “missing” cases WHO Global TB Report 2017

Estimated TB prevalence before and after prevalence surveys WHO Global TB Report 2017

Incidence estimates before and after surveys 2012-2015 WHO Global TB report 2016

Kenya Releases Results of National TB Prevalence Survey: March 24, 2017 NAIROBI —  Kenya on Friday recognized World Tuberculosis Day by releasing results of a TB study by the country's ministry of health — the first of its kind since Kenya's independence. TB remains high in Kenya, and experts say the country lags in the fight against the disease. The report states that there are more TB cases in Kenya than previously estimated, with a TB prevalence of 558 per 100,000 people.

Prevalence survey, Kenya Translates to approx. 138,105 incident cases/year compared with 82,000 reported 2015 (40% missing)

Many prevalent cases don’t report cough Nigeria and Indonesia – here 2/3-3/4 (65-75%) of S+ cases in community have screening positive symptoms, chronic cough; programmes can do much more here with available tools. Myanmar and Cambodia surveys reported where those who did not report screening positive symptoms whether they had sought care.

Sensitivity of microscopy 60% Kenya 32% Range ~30-60% sensitivity

False-positive smears are common

Cascade of Care: India -28% -12% -7% -5% -6%

13-Country Patient Pathway Summary 1. Initial General Care Seeking Patterns L0 0% 90% 42% 23% 2% 89% 71% 43% 2. Coverage of Microscopy Among Health Facilities L0 0% 29% 19% 4% 88% 69% 67% 10% 4. Coverage of Treatment Among Health Facilities 43% Missing 5% Private 52% Public Sector 6. Location of Notification (Among Estimated Burden) 43% Missing 7% Tx Not Succes. 48% Tx Succes. 7. Treatment Outcomes (Among Estimated Burden) 10% Private 19% Public Sector 3. Access to Microscopy at Initial Care Seeking 7% Private 23% Public Sector 5. Access to Treatment at Initial Care Seeking Patients may iterate through the diagnosis pathway multiple time before being initiated on treatment. 39% Public Sector 40% Private Sector 21% Informal Private Sector Sector 8% L0 17% L1 15% L2 20% 12% 21% L3 7% Level DRAFT VERSION 1.0

Where do we go from here? (1) Fix the front end of the care cascade (access and diagnostic capacity) Strengthen primary care services Align services with care seeking patterns Fully engage the private sector Purchase, deploy, and fully utilize rapid molecular testing that includes drug susceptibility testing (at least RIF) Hold the health care system to a high standard Integrated view of public and private as part of overall system Integration of TB services into primary and referral levels of care Improve information systems Apply performance criteria to all

Criteria for assessment of health system/facility performance Access and responsiveness Availability Timeliness of services Hospitality Quality Comprehensiveness Accuracy Adherence to standards Outcomes Treatment success Coverage Morbidity/mortality Accountability, transparency, regulation Data accessibility and quality Public health functions Reform capacity Fairness and equity Financial barriers to care Availability commensurate with need Efficiency Cost Redundancy Fragmentation Delays Basu S, et al. Comparative Performance of Private and Public Healthcare Systems in Low- and Middle- Income Countries: A Systematic Review. PLoS Med 9(6): e1001244. doi:10.1371/journal.pmed.1001244

Where do we go from here? (2) Improved approaches to case-finding and prevention Identification of high risk populations for screening Utilize more sensitive screening tests and algorithms Chest radiography (digital radiography) CRP followed by radiograph or rapid molecular test Begin implementation of treatment for LTBI in persons with high risk of TB 12 dose INH/rifapentine 30 day INH/rifapentine

Individual and community-centered care AA Information systems Universal coverage Access Social protection Technical assistance Ending TB Quality Funding Multi-stakeholder involvement Innovation Accountability Equity, rights Leadership